AstraZeneca stock gapped higher Friday as cancer drugs Enhertu and Tagrisso lent themselves to a solid third-quarter report. The post AstraZeneca Gaps Up To Three-Month High As CEO Calls Out $20 Billion Potential appeared first on Investor's Business Daily.
CryptoAlerta — análise de criptomoedas e mercado em tempo real